Tirzepatide: The Dual-Receptor Innovation Tirzepatide represents the next generation of weight loss medication
During that time period, people taking liraglutide reported 30% fewer cravings than those who took a placebo, and those taking buprenorphine at the same time were also more likely to report experiencing no cravings at all
Maintaining 64 to 80 ounces of daily fluid intake, increased further during GI symptoms, prevents this rare but serious complication
However, it does suggest a biologically plausible reason some people report reduced urges related to alcohol, food, or other compulsive patterns
Kidney function tests , including serum creatinine, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio (UACR), warrant attention